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Abstract
Background: In much of Africa, most individuals living with HIV do not know their status. Home-based counseling
and testing (HBCT) leads to more HIV-infected people learning their HIV status. However, there is little data on
whether knowing one’s HIV-positive status necessarily leads to uptake of HIV care, which could in turn, lead to a
reduction in the prevalence of common infectious disease syndromes.
Methods: In 2008, Kenya Medical Research Institute (KEMRI) in collaboration with the Centers for Disease Control
and Prevention (CDC) offered HBCT to individuals (aged ≥13 years) under active surveillance for infectious disease
syndromes in Lwak in rural western Kenya. HIV test results were linked to morbidity and healthcare-seeking data
collected by field workers through bi-weekly home visits. We analyzed changes in healthcare seeking behaviors
using proportions, and incidence (expressed as episodes per person-year) of acute respiratory illness (ARI), severe
acute respiratory illness (SARI), acute febrile illness (AFI) and diarrhea among first-time HIV testers in the year before
and after HBCT, stratified by their test result and if HIV-positive, whether they sought care at HIV Patient Support
Centers (PSCs).
Results: Of 9,613 individuals offered HBCT, 6,366 (66%) were first-time testers, 698 (11%) of whom were HIV-infected.
One year after HBCT, 50% of HIV-infected persons had enrolled at PSCs – 92% of whom had started cotrimoxazole and
37% of those eligible for antiretroviral treatment had initiated therapy. Among HIV-infected persons enrolled in PSCs,
AFI and diarrhea incidence decreased in the year after HBCT (rate ratio [RR] 0.84; 95% confidence interval [CI] 0.77 – 0.91
and RR 0.84, 95% CI 0.73 – 0.98, respectively). Among HIV-infected persons not attending PSCs and among
HIV-uninfected persons, decreases in incidence were significantly lower. While decreases also occurred in rates
of respiratory illnesses among HIV-positive persons in care, there were similar decreases in the other two groups.
Conclusions: Large scale HBCT enabled a large number of newly diagnosed HIV-infected persons to know their
HIV status, leading to a change in care seeking behavior and ultimately a decrease in incidence of common
infectious disease syndromes through appropriate treatment and care.
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Background
After three decades of the HIV epidemic in sub-Saharan
Africa, in many parts of the continent many people still do
not know their HIV status [1-5]. This is due to multiple
factors including low perception of risk, distance to HIV
testing centers, costs incurred in getting tested, and on-
going stigma of being HIV-infected [6,7]. Two national
AIDS indicator surveys have been done in Kenya. In the
first survey in 2007, only 34% of adults nationwide had
been tested before, and among those found to be HIV-
infected, only 16% correctly reported their HIV status.
These proportions increased to 72% and 47% respectively
in the second survey in 2012 [1,2,4]. Without knowledge
of their HIV status HIV-infected persons do not access
HIV care and treatment services, including cotrimoxazole
prophylaxis for opportunistic infections and antiretroviral
therapy (ART), nor are they likely to receive adequate
treatment for acute illness episodes [8-11].
Because the majority of HIV-infected persons not in
care are those that do not know their HIV status, mass
initiatives to test more persons for HIV are needed [12].
One strategy for increasing the number of individuals
who know their HIV status is home-based HIV counse-
ling and testing (HBCT) [4,13,14]. HBCT can overcome
barriers of cost, time-expenditure and stigma that pre-
vent many persons in rural Africa from seeking volun-
tary counseling and testing (VCT) at fixed facilities
[13-15]. While it has been shown that HBCT can
increase HIV testing and the number of people who
know their HIV status, it is not clear whether know-
ledge of HIV status influences care seeking which in
turn impacts incidence of common infectious illnesses
such as acute respiratory illness, febrile illness and
diarrhea whose burden is high in several parts of Africa
[16]. We hypothesize that as more people know their
HIV status, enroll into HIV care and treatment, and
receive highly-active antiretroviral treatment and cotri-
moxazole prophylaxis that the incidence of infectious dis-
ease morbidity will decrease in the community. We
further hypothesize that as people newly learn their HIV-
status they will be more likely to seek care for common
infectious disease syndromes, either because their access
to care has improved or their health awareness and con-
cern has increased due to learning their HIV status. We
describe the impact of a large-scale HBCT program
among newly diagnosed HIV-infected residents in the year
after HBCT in a high HIV prevalence population under
ongoing surveillance for common infectious disease
syndromes in rural western Kenya.
Methods
Study site and surveillance population
Since 2005, the Lwak area has been the site of population-
based infectious disease surveillance (PBIDS) run by the
Kenya Medical Research Institute (KEMRI) in collab-
oration with the U.S. Centers for Disease Control and
Prevention (CDC), (Figure 1). The PBIDS catchment
area has an average population of 25,000 people living
in 33 villages that are within a 5 kilometer radius of
Lwak Hospital, the project’s designated referral health
facility. The Lwak area is culturally homogeneous (95%
Luo ethnicity), and poor, with the primary economic
livelihood being subsistence farming and fishing [17,18].
Houses are predominantly clustered into compounds
comprised of houses for the male head of household, his
wives, and sons. Compounds are dispersed and lie
adjacent to the households’ agricultural fields. There are a
few clay or soil roads in the area and one tarmac road,
completed in 2006. The most common mode of transpor-
tation is by walking or bicycle taxi.
According to the most recent national HIV/AIDS survey
in 2012, Nyanza Province, where Lwak PBIDS is located,
has the highest HIV prevalence in Kenya – 15% for the
adult population [1,4]. The first HIV/AIDS survey in 2007
showed that only 34% of adults aged 15 years and above in
the province had ever been tested before for HIV. How-
ever, the 2012 survey showed a marked increase to 72%.
The PBIDS area also has one of the highest rates of
malaria in Africa. In fact, it is holoendemic, − almost
everyone in the population is infected with malaria [16,19].
Household surveillance
PBIDS household surveillance methods have been de-
scribed previously [16,20]. In brief, community inter-
viewers visit enrolled households every two weeks. The
catchment population includes people living within a
5 km radius of Lwak hospital, the project’s referral
facility. Participants are asked standardized questions,
in the local language, about recent illnesses and care
seeking. For certain key symptoms – cough, fever and
diarrhea – the exact days of occurrence are recorded.
For older children (over 12 years old) and adults, inter-
views of that person are done. If not at home or unable
to answer questions (i.e. children ≤ 12 years old and cogni-
tively impaired persons), a proxy who is knowledgeable
about the participant’s health completes the interview.
Abbreviated physical exams are carried out on ill
persons present during the visit, including axillary
temperature and observation for signs of dehydration.
Home-based counseling and testing
In early 2008 HBCT services were initiated and offered
to 12,149 PBIDS residents free of charge in their homes;
9,613 (79%) accepted and were HIV-tested [15]. To
participate in HBCT, one needed to be a resident in the
PBIDS area and also provide consent for participation.
A team of trained non-resident HIV counselors pro-
vided HIV testing and counseling at home to residents
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≥13 years of age who gave consent [13,15]. Rapid HIV
testing was done according to the National AIDS/STD
Control Program (NASCOP) algorithm using two paral-
lel HIV rapid tests (Determine™, Abbott Laboratories,
USA) and Bioline™ (Standard Diagnostics, Kyonggi-do,
Korea) with a tie-breaker test for discordant results
(Uni-gold™, Trinity Biotech, Ireland). For individuals
newly diagnosed with HIV counselors collected
additional finger-prick blood samples for CD4 testing
[21]. These blood samples were tested at the KEMRI/
CDC laboratories in Kisumu, and results made available
at Lwak Hospital within five days. One month following
HBCT, the same counselors made follow-up visits to
newly diagnosed HIV-infected persons to offer further
counseling and deliver CD4 results. At the follow-up
visits, we collected data on whether the clients had
visited an HIV Patient Support Center (PSC) and
whether they had started any HIV treatment since HBCT.
Counselors also encouraged those that had not enrolled in
HIV care to do so at any of the four nearby clinics
within the PBIDS area where free HIV care and treat-
ment services were provided.
Clinical care
Since 2005, PBIDS residents have received free medical
care at Lwak Hospital for all acute, potentially infectious
disease conditions by KEMRI/CDC-trained clinical
officers (equivalent to physician assistants) and nurses.
In 2007 Lwak Hospital, through support from the
President’s Emergency Plan for HIV/AIDS Relief (PEP-
FAR), began providing free HIV care and treatment
services. At the start in 2007, the clinic was only ope-
rational once a week on Mondays, and later increasing
operations to five days a week in 2008 with an expanded
team of nurses, clinical officers and counselors. HIV-
infected clients could also continue to access free clinical
care for illnesses through the PBIDS staff, as both the
PBIDS clinic and the PSC were located at Lwak Hospital.
PBIDS residents who chose to access services at any of the
three other health facilities could receive free HIV care
and treatment services, but unlike at Lwak would need to
pay facility fees for acute illness episodes.
Data collection and analysis
HIV testing and home follow-up visit data were
collected on paper forms (TeleForm®, Cardiff™, Vista,
CA), and later scanned and stored in Microsoft Access.
PBIDS data were collected using personal digital assis-
tants (PDAs) [20,22]. Medical chart data on those PBIDS
residents enrolling in HIV care at Lwak Hospital were
linked to other data using unique ID numbers. Data
from the other three health facilities were abstracted
using a standardized form and linked back to individuals’
HBCT data through the use of unique ID numbers when
available, and when not available, through a combination
of names, gender, age/date of birth and place of residence.
Our analysis was restricted to first-time testers who
also had data from household morbidity surveillance
available; therefore, the included sample was slightly
different from that of previously reported results from
HBCT [15]. We focus the analysis on first-time testers
because they provide the clearest indication of how
learning one’s HIV status affects health-seeking and
disease incidence.
We calculated the pre and post-HBCT incidence of
four syndromes namely acute respiratory illness (ARI),
severe acute respiratory tract illness (SARI), acute febrile
illness (AFI) and diarrhea using data from the household
visits. We defined ARI as cough or difficult breathing.
The definition of SARI included documented fever with
either cough or difficult breathing or chest pain [23].
AFI was defined as the presence of subjective or docu-
mented fever. Diarrheal illness was defined as an illness
in which at least three looser than normal stools were
reported during a 24-hour period. Each of these syn-
dromes was measured at a binary level as being either
present or absent. Using the biweekly household visit
data, we calculated incidence, as the number of illness
Figure 1 KEMRI/CDC’s Population based disease surveillance site in rural western Kenya.
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episodes per person-year in pre-HBCT and post-HBCT
periods. We used three symptom free days as the
minimum interval to distinguish different episodes of
diarrhea and seven symptom free days to distinguish
episodes of respiratory and febrile illnesses [16]. The
pre-HBCT period included episodes recorded in the
year before the HIV test date for each individual, while
the post-HBCT captured illnesses in the year following
HIV testing. PBIDS interviewers were blinded to
respondents HIV status. Because the annual HIV inci-
dence is estimated as 1.5% in the area (KEMRI/CDC
unpublished data), we assumed an individual’s HIV
status at HBCT would likely be the same in both pre-
and post-HBCT periods. The person-time contribution
was computed for each individual both pre- and post-
HBCT, which were summed to give the denominator
for incidence calculations. Using household data, we
compared pre- and post-HBCT proportions of each
syndrome among persons seeking care. We did not
evaluate incidence of the syndromes based on clinic
visitation. This was because if health-seeking to the
clinic changed after HBCT, as we speculated, then
rates of disease syndromes would reflect changes in
health-seeking rather than true changes in disease inci-
dence. To measure changes in severe disease, we used
rates of hospitalization, which we felt were less subject
to temporal changes in health-care seeking since
standardized clinical criteria for hospitalization irrespective
of HIV status were used. We compared pre-post HBCT
incidence among three groups of individuals – newly HIV-
infected and enrolled in HIV care, newly HIV-infected and
not enrolled in HIV care, and HIV-uninfected persons.
The first two groups were compared to reveal whether
any changes in morbidity could be ascribed to enrolling
into HIV care programs, rather than to changes in
reporting or perception of illness that occurred by just
testing positive in HBCT. The HIV-negative group was
included to control for secular changes in the health-
care seeking and disease incidence in the area that were
unrelated to HBCT.
For each syndrome in each period, we calculated inci-
dences, adjusted for age and sex. We controlled for
clustering of symptoms at the household level using
generalized estimating equations (GEE) [16]. Rates and
rate ratios were calculated using Poisson regression
(PROC GENMOD, SAS version 9.1, SAS Institute, Cary,
North Carolina, USA.
Ethical review
The protocol and consent forms were reviewed and
approved by the Ethical Review Boards of KEMRI (SSC 932)
and the Institutional Review Board of CDC (IRB 4566).
Signed participant consent was obtained for linking of HIV
data to individuals’ morbidity and demographic data.
Results
Of 9,613 individuals aged ≥13 years who received HIV
testing between January 2008 and February 2009, 6,366
(66%) participants were tested for their first time – 57%
being female, (Table 1). Overall HIV prevalence among
first-time testers ≥13 years was 10.9%; 8.6% in males
versus 12.7% in females and peaked in people in 35 –
49 year age group.
Among the 698 HIV-infected first-time testers, 219
(31%) had enrolled in HIV care by 3 months after HBCT,
50% had enrolled at one year and 58% by 24 months
(Figure 2). Over half (56%) who enrolled in care enrolled
at Lwak Hospital. There were no age or sex differences
in the proportions of HIV-infected people enrolled at
PSCs versus those HIV-infected but not enrolled (data
not shown). CD4 counts were available from 635 (91%)
of the first-time testers. No significant differences were
observed in the median CD4 counts for those who
enrolled for HIV care versus those who did not (402
cells/mm3, inter-quartile range 240 – 616 cells/mm3
versus 485 cells/mm3, inter-quartile range 347 – 583
cells/mm3). Of those enrolled at the PSCs according to
national guidelines at the time, 92% were initiated on
cotrimoxazole prophylaxis and 37% of people with
CD4 counts ≤250 cells/mm3 started taking antiretro-
viral drugs (ARVs) (Figure 3).
In all syndromes examined, more disease was reported
among HIV-infected persons than among uninfected
persons in the pre-HBCT period – 10% more for ARI,
25% more for AFI, 86% more diarrhea and 274% more for
SARI (Table 2). Overall, among HIV-infected persons
18.4% of household visits had an illness episode reported
in the year pre-HBCT and 17.2% in the year post-HBCT
(Table 3). In comparison, among HIV uninfected persons
15.6% of household visits had an illness episodes reported
in the year pre-HBCT and 13.5% in the year post-HBCT.
ARI and AFI were the most common syndromes in both
periods for both HIV-infected and uninfected persons.
Several notable trends were found in health-seeking for
common illnesses (Table 3). First, the percentage of
episodes resulting in a clinic visit was higher for all
syndromes among HIV-infected than uninfected persons,
both before and after HBCT. Second, the percentage of
episodes resulting in a clinic visit increased after HBCT for
all four syndromes among HIV-infected persons, although
only significantly for ARI (4.8% increase, [95% CI 2.3% –
7.3%]) and AFI (9.7% increase, [95% CI 6.6% – 12.8%]).
Health-seeking among HIV-infected persons increased
mostly at the designated PBIDS facility, Lwak Hospital.
Lastly, health-seeking increased more from pre- to
post-HBCT periods among HIV-infected persons than
uninfected persons for episodes of ARI (5.2% greater
increase, [95% CI 0.1% – 10.3%]) and AFI (7.0% greater
increase, [95% CI 0.6% – 13.4%).
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There was a significant reduction in rates of AFI (16%
decrease, [RR 0.84, 95% CI 0.77 – 0.91]) and diarrhea
(16% decrease, [RR 0.84, 95% CI 0.73 – 0.98]) among
HIV-infected individuals enrolled in a PSC in the post-
HBCT period compared to the pre-HBCT period
(Table 4). No difference was observed between the pre-
and post-HBCT periods in rates for any syndrome in
the HIV-infected group not enrolled in a PSC. In the
HIV-uninfected group, there was a significant 9% reduction
in ARI rate (RR 0.91, 95% CI 0.87 – 0.95), a 54% reduction
in SARI (RR 0.46, 95% CI 0.23 – 0.93), an 8% reduction in
the diarrhea rate (RR 0.92 95% CI 0.85 – 0.99), and an 8%
increase in the AFI rate (RR 1.08, 95% CI 1.03 – 1.14),
between pre- and post-HBTC periods. There was a greater
reduction in rates of AFI and diarrhea among HIV-
infected persons enrolled in a PSC than among either
HIV-infected persons not enrolled in a PSC or HIV-
uninfected persons. No significant differences were found
in pre-to-post-HBCT changes in the rates of ARI or
SARI between the three groups.
Among the group enrolled at PSCs, the overall
hospitalization rate in the post-HBCT period was 2.5
times higher (RR 2.57, 95% CI 1.59 – 4.16) than the
pre-HBCT period (Table 4). No changes were observed
in the hospitalization rates of those HIV-infected not
enrolled at PSCs or those who were HIV-uninfected.
Discussion
Our study was unique in showing that a mass campaign
of HBCT led to improvements in health-care seeking
and decreases in incidence of some common infectious
diseases among newly diagnosed HIV-infected persons.
HIV counseling and testing is considered the entry
point to HIV care, including access to cotrimoxazole







13-17 13/917 (1.4) 37/821 (4.5) 50/1738 (2.9)
18-34 93/888 (10.5) 215/975 (22.1) 308/1863 (16.5)
35-49 79/340 (23.2) 132/612 (21.6) 211/952 (22.2)
≥50 51/593 (8.6) 78/1220 (6.4) 129/1813 (7.1)
Total 236/2738 (8.6) 462/3628 (12.7) 698/6366 (10.9)
N = No. of people tested for their first time ever; n = no. with HIV.
Figure 2 Cumulative enrollment for HIV care at various clinics following HBCT in HIV-infected first-time lesters, western Kenya, 2008-2010.
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prophylaxis and antiretroviral treatment [9,12,24-26].
For those persons who did access a PSC, the majority
received appropriate treatment for HIV. The greater
than 90% use of cotrimoxazole in those enrolled for
HIV care in our study area was commendable and was
in line with the Ministry of Health’s guidelines for
universal use of cotrimoxazole irrespective of CD4 levels
[27]. We found that 37% of newly-diagnosed HIV-
infected persons who qualified for ARV (CD4 count
<250 cells/mm3) had started this treatment.
Reductions in morbidity, mortality, HIV incidence and
transmission, are the ultimate goal of large-scale efforts
at counseling and testing as people may likely enroll for
HIV care if they know they are HIV-infected [12,13].
Our study was one of the first to demonstrate a likely
causal sequence between HBCT, accessing HIV care and
treatment, and reduction in infectious disease morbidity.
Among those newly diagnosed persons who accessed
a PSC, we observed a 16% decline in incidences of
diarrhea and acute febrile illnesses. The decline likely re-
sulted, at least in part, from cotrimoxazole prophylaxis,
which is known to reduce infectious disease morbidity
[9,14,28-33]. Cotrimoxazole prophylaxis has been shown
to reduce diarrhea in several previous studies in Africa,
particularly from bacterial and parasitic causes [31-33].
Cotrimoxazole also has been demonstrated to be a
potent prophylactic against clinical malaria, with
reductions of more than 70% [31]. The Lwak area is a
malaria holoendemic area, where both children and
adults suffer from several clinical malaria episodes per
year [19]. Cotrimoxazole also likely reduces the occur-
rence of other causes of AFI besides malaria, such as
mycobacterial infections, bacteremia, and fevers of
unknown etiology [32,33]. In addition to cotrimoxa-
zole, initiation of ART has been shown to decrease
both diarrheal illness and undiagnosed acute febrile
illness in the first year after initiation of treatment.
Additionally, ART leads to reduction in the incidence of
known causes of AFI, such as bacteremia. We did not see
a significant decrease in respiratory illness among those
newly tested HIV-positive compared to the other two
groups. This may be due to the fact that much of ARI is
caused by viruses, which are generally not affected by
cotrimoxazole prophylaxis. Severe ARI is a rarer
syndrome and we might not have had the statistical power
to detect a significant decrease in our sample. Moreover,
there was a secular trend towards decreased SARI in the
population, as witnessed in the HIV-negative group, which
might have masked any specific impact of HIV treatment
on SARI rates.
Care-seeking for illnesses increased more among the
HIV-infected group in the post-HBCT period than the
uninfected group. Care-seeking increased more at Lwak
hospital than in the other three area clinics, which are
Figure 3 CTX/ARV use by CD4 level for HIV-infected first-time testers aged ≥13 years enrolled for HIV care, western Kenya, 2008-2010.
Guidelines in 2008 in Kenya recommend all HIV-infected persons with CD4 < 250 be started on ARVs.
Table 2 Comparing disease rates as episodes per person-year of observation (pyo) in pre-HBCT period among all





Rate ratio (95% CI)
(HIV infected/uninfected)
ARI 4.31 3.92 1.10 (1.06 – 1.14)
SARI 0.06 0.02 3.74 (1.83 – 7.66)
AFI 4.21 3.35 1.25 (1.13 – 1.40)
Diarrhea 1.50 0.81 1.86 (1.57 – 2.19)
ARI = Acute respiratory illness. SARI = Severe Acute Respiratory Illness. AFI = Acute febrile illness.
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run by the Ministry of Health (MOH). The greater
increase in care-seeking at Lwak hospital might have
been driven by several factors. First, the PBIDS field staff
making the biweekly home visits encouraged study
participants to go to Lwak hospital when ill. Second,
Lwak hospital provides free high-quality care to enrolled
study participants for all potentially infectious disease
syndromes, including free hospitalization if needed,
which is not available in other area MOH clinics [34].
Since access to free care was available at Lwak Hospital
in pre-and post-HBCT periods, a key difference in
motivation may, therefore, have resulted from an
increased knowledge of one’s HIV positive status.
Indeed, similar increases in attendance were not
observed for the HIV-uninfected group who served as a
comparison group to identify secular trends in health-
care seeking in the pre versus post-HBCT period.
We believe that the observed increase in hospitaliza-
tions among those with HIV enrolled at PSCs was
unlikely to be reflective of a true increase in severe dis-
ease among this group. As discussed, there was a general
increase in healthcare seeking among HIV-infected
persons, and therefore sicker patients were more likely
to be hospitalized. This was particularly true at Lwak
Hospital, because inpatient care was free for PBIDS
participants and standardized clinical criteria were used
for decisions on admission [16].
Approximately half of newly-diagnosed HIV-infected
persons attended PSCs in the follow-up period. Many
entered HIV care when their CD4 count was still rela-
tively high (median 402 cells/mm3), which enhanced
their ability to start prophylaxis before their disease had
progressed. The reasons why half of those testing posi-
tive for the first time did not access HIV care are not
clear. One possibility is that we missed some newly diag-
nosed persons who actually did attend a PSC. We only
followed up persons in their homes one month after
testing and then could only rely upon linking the names
and residences of persons from HBCT with those in the
registers of the area PSCs. This effort is limited by the
fact that often persons use alternate names and change
residences frequently [7]. It is also possible that indivi-
duals sought care in a clinic outside of the study area for
reasons of anonymity. Second, there is likely still a bar-
rier between HIV-testing and seeking care [7,35-37].
While doing HIV-testing in the home clearly overcame
some of the obstacles of stigma, as well as the actual and
opportunity costs of traveling to a fixed VCT center, the
same obstacles would still exist for those seeking care at
a PSC [6,37]. Further strategies are needed to improve
the uptake of HIV care services after HBCT.
Our study had several limitations. Our data was
limited to only one year of pre- and post-HBCT
surveillance. It is possible that decreases in disease
Table 3 Use of health care facilities by syndrome pre- and post-HBCT for first-time HIV testers, stratified by HIV
infection status, based on household morbidity surveillance data, western Kenya 2007 – 2010
HIV-infected persons, N = 698 HIV-uninfected persons, N = 5,668
Pre-HBCT Post-HBCT Diff. in % (95% CI) Pre-HBCT Post-HBCT Diff. in % (95% CI) Diff. of diffs*. (95% CI)
No. of household visits 15,421 16,757 128,837 138,801
ARI Episodes 2438 2507 18385 17167
n (%) to any clinic 563 (23.1) 701 (27.9) 4.8 (2.3 – 7.3) 2754 (14.9) 2491 (14.5) −0.4 (−1.1 – 0.3) 5.2 (0.1 – 10.3)
n (%) to Lwak 290 (11.9) 453 (18.1) 6.2 (4.2 – 8.2) 1326 (7.2) 1367 (7.9) 0.7 (0.1 – 1.3) 5.5 (1.4 – 9.6)
n (%) to other clinics 273 (11.2) 248 (9.9) −1.3 (−3.1 – 0.5) 1428 (7.8) 1124 (6.5) −1.3 (−1.8 – -0.8) 0.0 (−3.7 – 3.7)
SARI Episodes 18 26 37 32
n (%) to any clinic 5 (27.8) 11 (42.3) 14.5 (−57.6 – 28.6) 9 (24.3) 8 (25.0) 0.7 (−22.6 – 24.0) 13.8 (−82.2 – 109.8)
n (%) to Lwak 2 (11.1) 8 (30.8) 19.7 (−7.9 – 47.3) 3 (8.1) 4 (12.5) 4.4 (−12.9 – 21.8) 15.3 (−48.6 – 79.2)
n (%) to other clinics 3 (16.7) 3 (11.5) −5.2 (−31.1 – 20.7) 6 (16.2) 4 (12.5) −3.7 (−23.1 – 15.7) 8.9 (−54.5 – 72.3)
AFI Episodes 1746 1956 11224 13275
n (%) to any clinic 540 (30.9) 794 (40.6) 9.7 (6.6-12.8) 2567 (22.9) 3393 (25.6) 2.7(1.6 – 3.8) 7.0 (0.6 – 13.4)
n (%) to Lwak 255 (14.6) 526 (26.9) 12.3 (9.7 – 14.9) 1175 (10.5) 1771 (13.3) 2.8 (2.0 – 3.6) 9.5 (4.2 – 14.8)
n (%) to other clinics) 285 (16.3) 268 (13.7) −2.6 (−5.0 – -0.2) 1392 (12.4) 1622 (12.2) −0.2(−1.0 – 0.6) 2.4 (−2.6 – 7.4)
Diarrhea Episodes 623 620 2694 2588
n (%) to any clinic 205 (32.9) 211 (34.0) 1.1 (−4.3 – 6.5) 494 (18.3) 469 (18.1) −0.2 (−2.3 – 1.9) 1.3 (−10.1 – 12.7)
n (%) to Lwak 116 (18.6) 146 (23.5) 4.9 (0.2 – 9.6) 249 (9.2) 263 (10.2) 1.0 (−0.6 – 2.6) 3.9 (−5.8 – 13.6)
n (%) to other clinics) 89 (14.3) 65 (10.5) −3.8 (−7.6 – 0.0) 245 (9.1) 206 (8.0) −1.1 (−2.7– 0.5) 2.7 (−5.4 – 10.8)
*Difference of differences is the difference between the percentage of persons with illness seeking care pre- and post-HBCT with HIV infection minus the
percentage of persons with illness seeking care pre- and post-HBCT without HIV infection.
ARI = Acute respiratory illness. SARI = Severe Acute Respiratory Illness. AFI = Acute febrile illness.
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Table 4 Comparing disease incidence and hospitalization rates, (as episodes/person-year of observation (pyo)) for
first-time testers in the years before and after HBCT in, I) HIV-infected individuals enrolled for HIV care, II) HIV-infected
individuals not in HIV care, III) HIV-uninfected individuals, western Kenya, 2007 – 2010
I II III
HIV-infected and enrolled for
HIV care (n = 351)
HIV-infected and not
enrolled for HIV care
(n = 347)
HIV-uninfected group (n = 5668)
Episodes/pyo Episodes/pyo Episodes/pyo Ratio of rate ratio
(95% CI)
Syndrome Pre-HBCT Post-HBCT Rate ratio (95% CI) Pre-HBCT Post-HBCT Rate ratio (95% CI) Pre-HBCT Post-HBCT ratio Rate
(95% CI)
I vs II I vs III
ARI 4.42 4.30 0.97 (0.89 – 1.06) 4.30 3.72 0.86 (0.70 – 1.06) 3.92 3.57 0.91 (0.87 – 0.95) 1.13 (0.83 – 1.53) 1.07 (0.79 –1.43)
SARI 0.06 0.03 0.46 (0.14 – 1.52) 0.05 0.02 0.32 (0.03 – 3.09) 0.02 0.01 0.46 (0.23 – 0.93) 1.44 (0.90 – 2.33) 1.00 (0.66 –1.54)
AFI 4.97 4.18 0.84 (0.77 – 0.91) 3.51 3.58 1.02 (0.82 – 1.27) 3.35 3.62 1.08 (1.03 – 1.14) 0.82 (0.74 – 0.90) 0.77 (0.70 –0.85)
Diarrhea 1.38 1.16 0.84 (0.73 – 0.98) 0.95 0.95 1.00 (0.67 – 1.51) 0.81 0.74 0.92 (0.85 – 0.99) 0.84 (0.76 – 0.92) 0.91 (0.83 – 1.00)
Hospitalization
from any cause
0.07 0.19 2.57 (1.59 – 4.16) 0.08 0.15 1.74 (0.76 – 3.98) 0.04 0.05 1.27 (1.00 – 1.61) 1.48 (1.00 – 1.61) 2.02 (1.18 – 3.46)



















incidence among HIV-infected persons was due to an-
nual variations in disease burden, which might not
have been observed with more years of pre- and post-
HBCT surveillance. However, the fact that we found
differences in the reduction in disease between HIV-
infected persons on treatment versus HIV-infected
persons not on treatment and HIV-uninfected persons
suggests that the reduction in disease was specific to
receipt of HIV care and treatment. Second, the limited
time periods of surveillance did not allow us to moni-
tor the impact of care seeking on mortality as this is
still a relatively rare event. Moreover, temporal factors
might have influenced morbidity and mortality in this
time period, particularly post-election violence that
occurred in Kenya in 2008 [18]. Third, we assumed
that the HIV status at the time of HBCT was the same
for that individual in the year before and after testing.
While we believe misclassification of HIV status was
rare at the population level (1.5% annual incidence), it
might have introduced slight bias in the morbidity
findings due to acute illness symptoms with acute HIV
seroconversion [38]. Lastly, we only followed-up HIV-
positive clients at home one month after HBCT, which
would not have documented those who sought care
later; although we did search records for local PSCs
later to try to capture those who might have registered
later.
Conclusions
In summary, we demonstrated that HBCT led to a sub-
stantial number (approximately 700 or 11% of first-time
testers) of persons learning their HIV status for the first
time. Newly diagnosed HIV-infected persons had a
reduction in common infectious disease syndromes,
likely through increased access to HIV care and treat-
ment. While we did not demonstrate it, other studies
suggest that HBCT, by improving access to HIV care
and treatment, could lead to reductions in mortality and
HIV transmission [12,24,25,30]. We believe such impact
of HBCT on morbidity can be realized in other African
populations in which many persons do not know their
HIV status. However, we do caution that in order to
realize the full benefits of HBCT enhanced efforts are
needed to ensure those who test positive successfully
enter HIV care and treatment.
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